Wednesday, 23 May 2012 | Source: The Associated Press
Nektar Therapeutics shares rose Wednesday after a Jefferies & Co. analyst started covering the stock with a "Buy" rating, pointing to its promising drug pipeline.
Culled from thousands of pages of 2012 outlook reports, 13 stocks are being called “The Most Recommended Stocks for 2012”, according to a new report from Birinyi Associates... Read More